There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Immunic Inc. (IMUX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.01, or 0.64%, to $1.57. The Immunic Inc. has recorded 7,186 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.56 and fluctuated between $1.5700 as its day high and $1.4300 as its day low. The current market capitalization of Immunic Inc. is $67.72M. A total of 1.29 million shares were traded on the day, compared to an average of 2.80M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, IMUX has seen 5 BUY and 0 SELL insider trades, representing the acquisition of 113,000 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 1 SELLs from insiders. Insiders purchased 138,000 shares during that period but sold 6,000.
In the most recent transaction, Neermann Joerg bought 47,000 shares of IMUX for 1.26 per share on Dec 14. After the transaction, the Director now owns 100,000 company shares. In a previous transaction on Dec 13, Neermann Joerg bought 35,000 shares at 1.25 per share. IMUX shares that Director owns now total 53,000.
Among the insiders who bought shares, Neermann Joerg acquired of 18,000 shares on Nov 23 at a per-share price of $1.39. This resulted in the Director holding 18,000 shares of IMUX after the transaction. In another insider transaction, Vitt Daniel bought 8,000 shares at $1.35 per share on Nov 22. Company shares held by the President and CEO now total 376,877.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for IMUX in the last 3 months, the mean price target is $18.40 with high estimates of $39.00 and low estimates of $5.00. In terms of 52-week highs and lows, IMUX has a high of $14.50 and a low of $1.11.
As of this writing, IMUX has an earnings estimate of -$0.66 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.56 per share and a lower estimate of -$0.7. The company reported an EPS of -$0.74 in the last quarter, which was 7.50% higher than expectations of -$0.8.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMUX is Overweight with a score of 4.67. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.